P. Hildebrandt

P. Hildebrandt, J. Faber, F. Gustafsson, 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Prevalence and characteristics of heart failure clinics in Denmark—design of the Danish heart failure clinics network

P. Hildebrandt, F. Gustafsson, H. Villadsen, 2005, European journal of heart failure.

Is digoxin an independent risk factor for long-term mortality after acute myocardial infarction?

L. Køber, P. Høilund-Carlsen, P. Hildebrandt, 1994, European heart journal.

N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism.

P. Hildebrandt, J. Faber, C. Kistorp, 2007, Thyroid : official journal of the American Thyroid Association.

Reduced infarct size in nonreperfused myocardial infarction by combined infusion of isosorbide dinitrate and streptokinase.

P. Hildebrandt, C. Torp-Pedersen, G. Jensen, 1992, American heart journal.

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.

J Herlitz, H Wedel, M. Laakso, 2005, European heart journal.

Do patients necessarily have to start with an angiotension converting enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE Inhibitor Remodeling Mild CHF Evaluation) study

S. Pocock, L. Rydén, M. Komajda, 2003 .

Replacement of angiotensin converting enzyme inhibition by carvedilol results in long-term reversed left ventricular remodeling in mild heart failure and is well tolerated: Results of the CARMEN (Carvedilol aceinhibitor remodeling in mild heart failure evaluation) study

L. Rydén, M. Komajda, W. Remme, 2003 .

774 Plasma adiponectin, body mass index and mortality in patients with chronic heart failure

J. Frystyk, P. Hildebrandt, S. Galatius, 2005 .

Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: the Frederiksberg heart failure study.

G. Lip, P. Hildebrandt, A. Chong, 2007, International journal of cardiology.

Long-term prognosis after acute myocardial infarction in patients with a history of arterial hypertension

L. Køber, P. Hildebrandt, M. Ottesen, 1998 .

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.

P. Hildebrandt, J. Faber, F. Gustafsson, 2005, JAMA.

N‐terminal‐pro‐B‐type natriuretic peptide (NT‐pro‐BNP) in different thyroid function states

P. Hildebrandt, J. Faber, F. Pedersen, 2004, Clinical endocrinology.

Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study

O. Nielsen, P. Hildebrandt, G. Wikström, 2010 .

Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure.

C. Torp‐Pedersen, B. Brendorp, L. Køber, 2004, Journal of the American College of Cardiology.

High mortality among heart failure patients treated with antidepressants.

K. Veien, P. Hildebrandt, F. Gustafsson, 2011, International journal of cardiology.

Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction

P. Hildebrandt, F. Gustafsson, M. Schou, 2007, European journal of heart failure.

Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study.

H. Sørensen, P. Hildebrandt, C. Larsen, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.

Hans Eiskjær, Finn Gustafsson, Eva Korup, 2016, The New England journal of medicine.

Natriuretic Peptides: Prediction of Cardiovascular Disease in the General Population and High Risk Populations

P. Hildebrandt, 2009, Disease markers.

Value of N-Terminal proBNP in the Diagnosis of Left Ventricular Systolic Dysfunction in Primary Care Patients Referred for Echocardiography

P. Hildebrandt, F. Gustafsson, Jørn Badskjær, 2003, Heart Drug.

Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations.

P. Hildebrandt, H. Larsson, B. Groenning, 2002, American heart journal.

Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex

T. Hansen, C. Torp‐Pedersen, M. Olsen, 2008, Journal of hypertension.

N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.

T. Hansen, C. Torp‐Pedersen, M. Olsen, 2007, European heart journal.

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy

R. Devereux, S. Kjeldsen, M. Olsen, 2006, Journal of hypertension.

Incidence of cancer in patients with chronic heart failure: a long‐term follow‐up study

L. Køber, P. Hildebrandt, C. Torp-Pedersen, 2016, European journal of heart failure.

Recurrent acute idiopathic pericarditis treated with intravenous methylprednisolone given as pulse therapy.

P. Hildebrandt, C. Torp-Pedersen, T. Melchior, 1992, American heart journal.

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina

Gebhardt, D. DeMets, A. Capucci, 1998 .

Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure.

P. Hildebrandt, H. Larsson, L. Søndergaard, 2000, Journal of the American College of Cardiology.

Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care.

R. Doughty, P. Collinson, P. Hildebrandt, 2010, European heart journal.

Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide

J. Hilden, J. Kastrup, G. Jensen, 2014, European journal of preventive cardiology.

Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar).

P. Hildebrandt, K. Egstrup, C. Tuxen, 2013, European heart journal.

Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure.

I. Gustafsson, P. Hildebrandt, J. Goetze, 2012, The American journal of cardiology.

α‐Defensins and outcome in patients with chronic heart failure

J. Frystyk, P. Hildebrandt, A. Flyvbjerg, 2012, European journal of heart failure.

Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis

I. Gustafsson, P. Hildebrandt, C. Tuxen, 2011, European journal of heart failure.

L. Køber, I. Gustafsson, P. Hildebrandt, 1999, Journal of the American College of Cardiology.

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.

J. Kastrup, G. Jensen, P. Hildebrandt, 2009, European heart journal.

Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population.

H. Vestergaard, P. Hildebrandt, J. Faber, 2010, International journal of cardiology.

The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN)

L. Rydén, M. Komajda, W. Remme, 2004, Cardiovascular Drugs and Therapy.

Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure

Jan Frystyk, Finn Gustafsson, J. Frystyk, 2005, Circulation.

Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.

S. Yusuf, J. Bosch, B. Lewis, 2014, The lancet. Diabetes & endocrinology.

Neurohumoral prediction of left‐ventricular morphologic response to β‐blockade with metoprolol in chronic left‐ventricular systolic heart failure

P. Hildebrandt, A. Kjaer, H. Larsson, 2002, European journal of heart failure.

Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations

P. Hildebrandt, H. Larsson, L. Søndergaard, 2001, European journal of heart failure.

Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction.

K. Dickstein, I. Gustafsson, P. Hildebrandt, 2007, American heart journal.

Adding serial N‐terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study)

P. Hildebrandt, O. Nyvad, F. Gustafsson, 2013, European journal of heart failure.

Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study

D. Atar, P. Hildebrandt, S. Galatius, 2003, BMJ : British Medical Journal.

The Frederiksberg Heart Failure Study: Rationale, Design and Methodology, with Special Emphasis on the Sampling Procedure for the Study Population and Its Comparison to the Background Population

P. Hildebrandt, F. Pedersen, I. Raymond, 2002, Heart Drug.

An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area.

D. Atar, P. Hildebrandt, S. Galatius, 2002, American heart journal.

The prognosis of impaired left ventricular systolic function and heart failure in a middle‐aged and elderly population in an urban population segment of Copenhagen

J. Mehlsen, P. Hildebrandt, F. Pedersen, 2004, European journal of heart failure.

Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial.

J. Hilden, J. Kastrup, G. Jensen, 2014, American heart journal.

Combined Type 2 Diabetes and Ischemic Heart Disease: Double Jeopardy

P. Hildebrandt, J. Faber, 2001, Heart Drug.

Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial

M. Simoons, W. Remme, K. Fox, 2007, Heart.

Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population

H. Vestergaard, P. Hildebrandt, J. Faber, 2010, Inflammation Research.

Does in-hospital ventricular fibrillation affect prognosis after myocardial infarction?

P. Andersen, L. Køber, P. Hildebrandt, 1997, European heart journal.

The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial.

A. Brandes, J. Svendsen, C. Torp‐Pedersen, 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL.

J. Tardif, K. Fox, R. Ferrari, 2011, International journal of cardiology.

Metabolic syndrome and mortality in stable coronary heart disease: relation to gender.

L. Køber, P. Hildebrandt, R. Steffensen, 2007, International journal of cardiology.

Statin Treatment Prevents Increased Cardiovascular and All-Cause Mortality Associated With Clarithromycin in Patients With Stable Coronary Heart Disease

J. Hilden, J. Kastrup, G. Jensen, 2010, Journal of cardiovascular pharmacology.

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

Christian Gluud, Morten Damgaard, Jørgen Hilden, 2005, BMJ : British Medical Journal.

Effect of Beta-blockade and ACE Inhibition on B-type Natriuretic Peptides in Stable Patients with Systolic Heart Failure

W. Remme, P. Hildebrandt, G. Riegger, 2008, Cardiovascular Drugs and Therapy.

Mitral regurgitation determined by radionuclide cardiography: dependence on posture and exercise.

P. Hildebrandt, J. Aldershvile, K. Skagen, 1994, British heart journal.

Tolerability of carvedilol and ACE‐Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE‐Inhibitor Remodelling Mild CHF EvaluatioN)

L. Rydén, M. Komajda, W. Remme, 2004, European journal of heart failure.

Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy

H. Dige-Petersen, R. Devereux, S. Kjeldsen, 2005, Journal of Human Hypertension.

Prevalence of impaired left ventricular systolic function and heart failure in a middle aged and elderly urban population segment of Copenhagen

D. Atar, P. Hildebrandt, C. Tuxen, 2003, Heart.

N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults

P. Hildebrandt, J. Faber, F. Gustafsson, 2005 .

Unexplained week‐to‐week variation in BNP and NT‐proBNP is low in chronic heart failure patients during steady state

P. Hildebrandt, A. Kjaer, L. Madsen, 2007, European journal of heart failure.

Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide.

G. Jensen, P. Hildebrandt, H. Larsson, 2002, American heart journal.

Quantification of aortic regurgitation by magnetic resonance velocity mapping.

O Henriksen, F Ståhlberg, C. Thomsen, 1993, American heart journal.

Biochemical Cardiac Risk Markers in the General Population, Hypertension and Coronary Artery Disease

P. Hildebrandt, F. Pedersen, C. Kistorp, 2005, Scandinavian journal of clinical and laboratory investigation. Supplementum.

Impact of obesity on long-term prognosis following acute myocardial infarction.

L. Køber, C. Hassager, P. Hildebrandt, 2005, International journal of cardiology.

Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure

A. Brandes, J. Svendsen, L. Køber, 2017, Circulation.

Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses.

I. Gustafsson, P. Hildebrandt, M. Schou, 2012, Journal of cardiac failure.

Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.

P. Hildebrandt, L. Madsen, F. Gustafsson, 2007, International journal of cardiology.

Plasma YKL-40 levels are elevated in patients with chronic heart failure

G. Lip, H. Vestergaard, P. Hildebrandt, 2010, Scandinavian cardiovascular journal : SCJ.

Long-term clinical variation of NT-proBNP in stable chronic heart failure patients.

P. Hildebrandt, A. Kjaer, F. Gustafsson, 2006, European heart journal.

C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study

T. Hansen, J. Jeppesen, M. Olsen, 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Combination Therapy with Metolazone and Loop Diuretics in Outpatients with Refractory Heart Failure: An Observational Study and Review of the Literature

P. Hildebrandt, S. Galatius, F. Gustafsson, 2005, Cardiovascular Drugs and Therapy.

Prevalence of diastolic dysfunction as a possible cause of dyspnea in the elderly.

D. Atar, J. Mehlsen, P. Hildebrandt, 2005, The American journal of medicine.

Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure.

P. Hildebrandt, F. Gustafsson, P. Corell, 2005, Journal of cardiac failure.

Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.

Christian Gluud, Jørgen Hilden, J. Hilden, 2011, Atherosclerosis.

Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study

M. Eriksson, U. Laufs, J. Ferrières, 2021, Atherosclerosis plus.

Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide--three new cardiovascular risk markers--do they improve risk prediction and influence treatment?

T. Hansen, C. Torp‐Pedersen, M. Olsen, 2010, Current vascular pharmacology.